Philadelphia, Pennsylvania 19107

  • Isthmic Spondylolisthesis


The aim of this study is to compare outcomes and cost-effectiveness of anterior versus posterior surgical treatment for lumbar Isthmic Spondylolisthesis. The primary objective is to compare treatment effectiveness in terms of functional outcomes as measured by Oswestry Disability Index (ODI) v2.1a and to compare safety outcomes measured by treatment-related adverse events. Secondary objectives are to compare treatments in terms of differences in pain, quality of life, health utilities, and need for re-operation. Finally, a cost-effectiveness analysis will be performed. This analysis will take the form of cost-effectiveness if there is a difference in treatment effects or cost-minimization if there is no difference in treatment efficacy.


Inclusion Criteria: - Aged 18 to 80 years, inclusive - Grade I, II or III (less than 75% slip of the cephalad vertebra compared to the caudal vertebra) isthmic spondylolisthesis at single level between L4 and S1 - Unresponsive to a minimum of 3 months of non-surgical treatment - No previous surgical treatment for isthmic spondylolisthesis - Patients who are medically suitable for surgical management - Patients who have consented for surgical treatment - Willing and able to comply with the Investigational Protocol (IP) - Informed Consent Form (ICF) signed by patient Exclusion Criteria: - Any previous lumbar spine surgery - Patient has significant scoliosis (Cobb angle is greater than 25 degrees) - Subject has cauda equina syndrome defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction - Subject is pregnant or of child-bearing potential and not currently on adequate birth control method - Active infection at the surgical site - Recent history (less than 1 year) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation, in the opinion of the Investigator - Pre-existent neurologic or mental disorder which would preclude accurate evaluation and follow-up (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric disorder with hallucinations and/or delusions or schizophrenia - Participation in another clinical trial of drug or device within the past 30 days that could influence the outcomes of this study - Is a prisoner - Acquired immune deficiency syndrome (AIDS) or AIDS-related complex - Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated; patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study



Primary Contact:

Paul Arnold, MD
Phone: (913) 588-7587

Backup Contact:

Branko Kopjar, MD PhD
Phone: (206) 607-6861

Location Contact:

Philadelphia, Pennsylvania 19107
United States

James Harrop, MD
Phone: 215-955-7000

Site Status: Recruiting

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.